Exploring the anti-NSCLC mechanism of phillyrin targeting inhibition of the HSP90-AKT pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03481-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Qiong Duan und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Lianyungang Municipal Oriental Hospital of Xuzhou Medical University, Lianyungang, 222042, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, HSP90 Heat-Shock Proteins, Proto-Oncogene Proteins c-akt, Lung Neoplasms. Die Arbeit nennt 30 Literaturangaben. Gefördert von: the Department of Science and Technology of Lianyungang.
Abstract (Originalsprache)
Phillyrin (PHN), derived from the dried fruit of Forsythia suspensa (Thunb.) Vahl, is a kind of Chinese herbal medicine with the effect of clearing heat, and has been used in China for thousands of years in treating various tumors. However, the mechanism of its main components on non-small cell lung cancer (NSCLC) remains unclear. PHN is a distinct component extracted from Forsythia suspensa with promising anti-cancer activity against various tumor types. This study sought to elucidate the promising effects of PHN on NSCLC. Based on network pharmacology results, we identified potential PHN targets and pathways for NSCLC treatment. CCK-8 assay, wound healing assay, apoptosis assay, western blot, and in vivo experiments verified the inhibitory effect of PHN on NSCLC. Network pharmacology identified 160 potential PHN targets, 955 NSCLC-related targets, and 54 common targets, along with 132 pathways and 2 core genes. Biological experiments demonstrated that PHN significantly inhibited the growth and migration of A549 and LLC cells while promoting their apoptosis. Western blot analysis revealed down-regulation of AKT, HSP90AA1, and CDC37 expression, suggesting that PHN inhibits A549 and LLC cell proliferation by down-regulating the HSP90-AKT pathway. In vivo experiments confirmed that PHN significantly inhibited NSCLC growth with low toxicity. This study, using network pharmacology and biological experiments, verified the effectiveness of PHN against NSCLC through the HSP90-AKT pathway. These findings provide a foundation for further research and analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Lianyungang Municipal Oriental Hospital of Xuzhou Medical University, Lianyungang, 222042, China.
- Sichuan Integrative Medicine Hospital, Chengdu, 610000, China.
- The Affiliated Lianyungang Municipal Oriental Hospital of Xuzhou Medical University, Lianyungang, 222042, China. hanfeng135733@126.com.
- The Affiliated Lianyungang Municipal Oriental Hospital of Xuzhou Medical University, Lianyungang, 222042, China. mjx3416@163.com.
Förderung
- the Department of Science and Technology of Lianyungang
Zitieren
APA
Duan, Q., Li, R., Wang, M., Cui, Z., Zhu, X., Chen, F., Han, F., & Ma, J. (2025). Exploring the anti-NSCLC mechanism of phillyrin targeting inhibition of the HSP90-AKT pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03481-1
Vancouver
Duan Q, Li R, Wang M, Cui Z, Zhu X, Chen F, et al. Exploring the anti-NSCLC mechanism of phillyrin targeting inhibition of the HSP90-AKT pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03481-1
BibTeX
@article{Duan2025,
author = {Duan, Qiong and Li, Ruochen and Wang, Mingxiao and Cui, Zhenting and Zhu, Xia and Chen, Fanghong and Han, Feng and Ma, Jianxin},
title = {Exploring the anti-NSCLC mechanism of phillyrin targeting inhibition of the HSP90-AKT pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03481-1}
}
EUVIMED